10X Genomics, Inc. (TXG)
| Market Cap | 16.63B |
| Revenue (ttm) | 459.18M |
| Net Income (ttm) | -455.35M |
| Shares Out | 111.71M |
| EPS (ttm) | -4.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 645,903 |
| Open | 160.80 |
| Previous Close | 150.99 |
| Day's Range | 148.44 - 154.07 |
| 52-Week Range | 128.15 - 208.99 |
| Beta | 1.40 |
| Analysts | Buy |
| Price Target | 192.38 (+29.2%) |
| Earnings Date | Nov 3, 2021 |
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me...
Financial Performance
In 2020, 10X Genomics's revenue was $298.85 million, an increase of 21.53% compared to the previous year's $245.89 million. Losses were -$542.73 million, 1,636.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for 10X Genomics stock is "Buy." The 12-month stock price forecast is 192.38, which is an increase of 29.24% from the latest price.
News
10x Genomics Stock: Bull vs. Bear
After a hot start, the stock has recently lagged the market. Is now a good time to buy?
Better Buy: 10x Genomics vs. DermTech
Both companies offer disruptive new solutions in their niches of the healthcare space.
10x Genomics Clocks 74% Jump In Q3 Revenues; Raises Top End Of Sales Guidance
10x Genomics Inc (NASDAQ: TXG) reported Q3 sales of $125.3 million, beating the consensus of $122.62 million. Sales increased 74% Y/Y, primarily due to increased consumables revenue driven by growth in ...
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of 16.67% and 0.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics Reports Third Quarter 2021 Financial Results
PLEASANTON, Calif., Nov. 3, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2021.
10x Genomics Earnings Preview
10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics Celebrates Opening of Singapore Manufacturing and Commercial Hub
SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today marked a major Asia Pacific (APAC) expansion with ...
Wall Street Analysts See a 27% Upside in 10x Genomics (TXG): Can the Stock Really Move This High?
The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...
3 COVID Stocks That Can Turn $1,000 Into $10,000
Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.
10x Genomics to Report Third Quarter Financial Results on November 3, 2021
PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021.
Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges
Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.
Here's Why 10x Genomics (TXG) is Poised for a Turnaround After Losing 22.3% in 4 Weeks
10x Genomics (TXG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...
Why 10x Genomics Shares Are Trading Lower Today
10x Genomics (NASDAQ:TXG) shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and announced a $180 price target. 10x Genomics' stock is currently down 7.53% to a pr...
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
PLEASANTON, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes
10x Genomics to Report Second Quarter Financial Results on August 4, 2021
PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th,...
These 3 Cathie Wood Stocks Are Still Going Strong
Even with some setbacks in 2021, the ARK Invest manager has still found some winners.
Here's Why 10x Genomics Can't Satisfy Short-Term Investors
Long-term investors should keep perspective.
Strength Seen in 10x Genomics (TXG): Can Its 3.9% Jump Turn into More Strength?
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.